Quantity of suitable people: CDEC mentioned the uncertainty in the number of patients with moderately critical to serious hemophilia B in Canada eligible for etranacogene dezaparvovec. Medical industry experts consulted by CADTH indicated that some patients who will be labeled as obtaining moderate or reasonable illness might have a severe https://gailo023ikl7.wikimeglio.com/user